RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Synthesis and pharmacology of 11-nor-11-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: New selective ligands for the cannabinoid CB2 receptor
Marriott, KSC., Huffman, JW., Wiley, J., & Martin, BR. (2006). Synthesis and pharmacology of 11-nor-11-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: New selective ligands for the cannabinoid CB2 receptor. Bioorganic and Medicinal Chemistry, 14(7), 2386-2397.
Fourteen novel CB2 receptor selective cannabinoids were synthesized via initial Lewis acid catalyzed rearrangement of resorcinol precursors to obtain the cannabinoid moiety. These are the 1-methoxy-9-hydroxyhexahydrocannabinols and the 1-deoxy-9-hydroxyhexahydrocannabinols, with 1',1'-dimethylalkyl side chains of four to seven carbon atoms at C-3 of the cannabinoid nucleus. The cannabinols synthesized and described in this paper all exhibit greater affinity for the CB, receptor than for the CB1 receptor. Exceptionally high CB2 affinity was observed for 1-deoxy-9 beta-hydroxy-dimethylhexylhexahydrocannabinol (JWH-361, 9, n = 3) K-i = 2.7 nM and 1-deoxy-9 beta-hydroxydimethylpentyihexahydrocannabinol (JWH-300, 9, n = 2) K-i = 5.3 nM. In general, the stereochemistry of the 9-hydroxy group is important and the beta-orientation enhances both CB2 receptor affinity and selectivity. (c) 2005 Elsevier Ltd. All rights reserved